Biosyent Inc (TSE:RX) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
BioSyent Inc. has successfully extended its exclusive Canadian rights for RepaGyn® and Proktis-M® until 2032 through its subsidiary, BioSyent Pharma. These products, which address vaginal dryness and rectal healing respectively, have been a key part of BioSyent’s portfolio since 2014, contributing to the company’s commitment to offering safe and effective healthcare products. The extension signifies BioSyent’s ongoing dedication to growth and patient care within the specialty pharmaceutical market.
For further insights into TSE:RX stock, check out TipRanks’ Stock Analysis page.
